Stock ZYUS ZYUS LIFE SCIENCES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Other languages ZYUS Life Sciences Corporation

Equities

ZYUS

CA9899601095

Market Closed - Toronto S.E.
Other stock markets
 09:30:00 2024-05-31 am EDT 		5-day change 1st Jan Change
1.08 CAD +5.88% Intraday chart for ZYUS Life Sciences Corporation +5.88% +20.00%
May. 29 ZYUS Life Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 ZYUS Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ZYUS Life Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
ZYUS Announces Completion of Its Annual Filings
INSERTING and REPLACING ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9
ZYUS Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate
ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management
Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets
Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate
Calian Group Brief: Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate
ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke
ZYUS Life Sciences Appoints Dr. Hance Clarke to Clinical Advisory Committee
Zyus Appoints Dr. Hance Clarke as Clinical Advisory Committee
ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Management
ZYUS Life Sciences Corp. Announces Phase 2 Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Care
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain Management
ZYUS Life Sciences Corporation Reports Q3 2023 Results
ZYUS Life Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin Softgels
ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZYUS Stock
  4. News ZYUS Life Sciences Corporation
  5. Other languages